Status: Recruiting
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.
Participants needed: 39
Trial details
Phase: Phase 2Age: 18-100Biological sex: AllType: InterventionalSponsor: Peking Union Medical CollegeUpdated: Apr 2, 2026Locations: 2
Eligibility criteria
Patients with histopathologic diagnosis of salivary gland carcinoma [+4]
Known hypersensitivity or delayed anaphylaxis to any agents in this trial; [+7]